 |
|
Mesothelioma: A Killer
Lurks in the Lungs |
|
 |
Mesothelioma & Asbestos News Page
Home Page
SOURCE: Reuters Health
Celebrex Hits Mesothelioma, in Lab Studies
May 6, 2004
The COX-2 inhibitor Celebrex, usually prescribed for arthritis, has a marked effect on the asbestos-related cancer malignant mesothelioma in lab and animal experiments, according to a report from Italy.
Current treatments for mesothelioma have failed to alter its dismal prognosis, the authors comment in the International Journal of Cancer, but one selective COX-2 inhibitor has been shown to stop mesothelioma cells growing in a lab dish.
This prompted Dr. Alfonso Catalano at the University of Marche in Ancona and colleagues to assess the effects of Celebrex (a.k.a. celecoxib) on experimental mesothelioma.
Celecoxib and similar compounds all inhibited proliferation of a mesothelioma cell line without inhibiting the growth of a normal mesothelial cell line, the researchers report. Celecoxib was the most effective of the agents tested.
In mice implanted with mesothelioma, celecoxib treatment significantly increased average survival from 45 days to 62 days, the researchers note, and there were three long-term (more than 120 days) survivors among the treated mice.
"These results provide the first evidence that celecoxib is effective for the prevention and regression of malignant mesothelioma cells in experimental models ... and strongly support ongoing clinical trials in malignant mesothelioma patients," the team concludes.
SOURCE: International Journal of Cancer, April 10, 2004.
Back to Original Article on Mesothelioma
Continue with:
FDA Approves Alimta-Cisplatin Combination for Treatment of Asbestos-Related Cancer Mesothelioma The first and only drug regimen proven to help patients with an asbestos-related cancer live longer was approved today by the U.S. Food and Drug Administration (FDA).
Group Launches Asbestos-Cancer Study April 5, 2004 DETROIT - Karmanos Cancer Center is launching a comprehensive medical program to study the effects of asbestos-related cancers linked with contaminated vermiculite, a mineral used in insulation.
Study Supports Development Potential in Several Therapeutic Areas New Study Reviews Novel Approach to Control Inflammation Using Melanocortin Receptors WOODLAND HILLS, Calif., March 3 /PRNewswire/ -- Zengen, Inc. announced today that its researchers have discovered that activation of melanocortin receptors (MCR) subtypes MC1R and MC3R could be a novel strategy to control inflammatory disorders.
FDA Approves First Drug for Rare Type of Cancer The Food and Drug Administration (FDA) today approved Alimta (pemetrexed disodium) for use in combination with cisplatin for the treatment of patients with malignant pleural mesothelioma - a rare type of cancer. Alimta received a priority review and is designated as an orphan drug. It is the first drug approved for this condition.
|
